Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Akeso Says PD-1/VEGF Candidate Out-Performs Keytruda in NSCLC

publication date: May 31, 2024

Guangzhou’s Akeso reported that its bispecific antibody, ivonescimab, a combination of PD-1 and VEGF, posted better progression-free survival results than Merck’s Keytruda in patients with non-small cell lung cancer. It is the first time Keytruda was bested by another PD-1 candidate, according to the company. The data came from an interim analysis of ivonescimab in a China Phase III trial in NSCLC patients with positive PD-L1 expression. Specific data will be presented in an upcoming scientific meeting. In late 2022, Summit Therapeutics in-licensed US/EU/Japan rights for ivonescimab in a $5 billion deal. More details....

Stock Symbol: (HK: 9926)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here